Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPulmonologyallcareadvantage brensocatib Prior Auth Coverage |…
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 136.1

    Non-cystic fibrosis bronchiectasis agents (brensocatib)

    Customize your policy alerts

    Sign up for allcareadvantage Policy 136.1 alerts

    Get alerted when Policy 136.1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for formulary non-cystic fibrosis bronchiectasis agents (specifically brensocatib/Brinsupri) for AllCare Advantage members; governs coverage decisions for prescribers and pharmacy benefit staff.

    Policy Summary
    Payerallcareadvantage
    PolicyNon-cystic fibrosis bronchiectasis agents (brensocatib)
    Policy CodePolicy 136.1
    Change TypeNo material change
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2027
    Next Review DateDec 18, 2027
    Key ActionSubmit prior authorization with documentation of diagnosis by chest CT, trials and >75% adherence to standard preventive therapies, and two or more exacerbations in the prior year.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    brensocatibListed agent
    ≤6 moInitial approval
    ≤12 moRenewal approval
    Age ≥12FDA population

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met.

    Initial criteria: Member has a diagnosis of non-cystic fibrosis bronchiectasis (NCFB) confirmed by noncontrast chest CT; patient meets FDA-approved age labeling (>= 12 years); the requested agent is prescribed by a lung specialist; documentation of airway clearance therapy (or documentation of reason airway clearance is not used); member is established on standard-of-care preventive therapies (antibiotics, inhaled bronchodilators, and glucocorticoids) with good compliance (>75% adherence); documentation of two or more exacerbations in the prior year despite a trial of antibiotic therapy (e.g., macrolide) or an antipseudomonal inhaled antibiotic.see individual nodes

    If all met -> approve up to 6 months; if not met -> deny

    Continuation / Renewal

    Covered when ALL of the following are met.

    Renewal criteria: Member met the initial criteria at baseline AND there is documentation to support treatment efficacy (clinical benefit).documentation of benefit

    If met -> approve up to 12 months; if not met -> deny

    This policy applies to the FDA‑approved population for brensocatib (Brinsupri): treatment of non‑cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older. The diagnosis must be confirmed by noncontrast chest computed tomography (CT). Requests should be for maintenance/preventive therapy prescribed by a lung specialist, and documentation should address airway clearance therapy or provide a clinical reason for its absence.

    A request is considered not medically necessary when the member has not been established on standard preventive therapies for exacerbation reduction — specifically trials of antibiotics, inhaled bronchodilators, and glucocorticoids — with documented good adherence (≤75% adherence does not meet the policy requirement). Additionally, requests lacking documentation of two or more exacerbations in the prior year despite appropriate antibiotic therapy (e.g., macrolide) or an antipseudomonal inhaled antibiotic will be denied.

    Coding and Adherence Metrics

    Codes referencedmixed
    N/ADocument does not list specific CPT/HCPCS/ICD-10/NDC codes; refers generically to formulary agent(s) and quantity limits in formulary print document.
    Adherence threshold
    Adherence threshold>75% (member must be established on standard preventive therapies with good compliance)
    Context for useRequired when assessing step-therapy and prior authorization for NCFB agents; nonadherence may trigger denial
    Applies to therapiesAntibiotics, inhaled bronchodilators, and glucocorticoids as standard of care

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required; approval durations and FDA labeling

    Prior authorization is required for formulary non‑cystic fibrosis bronchiectasis agents. Initial approvals are for up to 6 months; renewals may be approved for up to 12 months. Member must meet FDA‑approved labeling (age ≥12 years) and the policy’s listed clinical criteria.

    Step Therapy

    Step‑therapy: trial of standard preventive therapies required

    Member must have tried/failed first‑line standard-of-care prevention therapies (antibiotics, inhaled bronchodilators, and glucocorticoids) and be established on these therapies with good compliance (>75% adherence) before a formulary agent will be approved.

    Documentation Required

    Required documentation to support prior authorization

    Provide documentation confirming diagnosis and prior treatments: non‑cystic fibrosis bronchiectasis diagnosis confirmed by noncontrast chest CT; documentation of airway clearance therapy (or reason it was not used); evidence of trials of standard preventive therapies and adherence (>75%); and documentation of two or more exacerbations in the prior year despite appropriate antibiotic therapy (e.g., macrolide) or an antipseudomonal inhaled antibiotic.

    Denial Risk

    Denial triggers: lack of prior standard therapy or documented exacerbations

    Requests will be denied if the member is not established on standard preventive therapies for exacerbation prevention (antibiotics, inhaled bronchodilators, glucocorticoids) with good adherence (>75%), or if there is no documentation of two or more exacerbations in the prior year despite trial of appropriate antibiotic or antipseudomonal inhaled antibiotic.

    Definitions

    Non‑cystic fibrosis bronchiectasis (NCFB) — diagnostic definition
    DefinitionNon-cystic fibrosis bronchiectasis (NCFB) — a chronic pulmonary condition characterized by irreversible bronchial dilation and recurrent exacerbations; FDA indication for brensocatib is NCFB in patients ≥12 years.
    Diagnostic confirmationDiagnosis must be confirmed by noncontrast chest computed tomography (CT).
    Radiographic criteriaRadiographic evidence consistent with bronchiectasis on noncontrast chest CT (irreversible bronchial dilatation).
    Age criterion (FDA labeling)Applies to patients 12 years of age and older per FDA-approved indication.
    Standard of care for prevention of exacerbations
    Standard therapies requiredAntibiotics, inhaled bronchodilators, and glucocorticoids must be used as standard of care for prevention of exacerbations before considering formulary agents.
    Adherence requirementDocumented adherence >75% to the above standard therapies is required prior to approval.
    Step-therapy roleMember must have tried/failed first-line treatments (the listed standard therapies) prior to approval of formulary agents.
    Documentation expectationsClinical records should show trials of these therapies and evidence of adherence when submitting prior authorization requests.

    Background

    Non‑cystic fibrosis bronchiectasis (NCFB) is a chronic pulmonary condition characterized by irreversible bronchial dilation and recurrent respiratory exacerbations; diagnosis is radiographic, typically by noncontrast chest CT. Clinical management focuses on preventing exacerbations and preserving lung function using airway clearance techniques plus pharmacologic measures. Standard preventive strategies include chronic or targeted antibiotic therapy, inhaled bronchodilators, and inhaled or systemic glucocorticoids where indicated; brensocatib (Brinsupri) is an additional option for patients meeting FDA labeling and the policy’s criteria when standard measures and documented adherence have failed to prevent recurrent exacerbations.

    Policy Summary
    Payerallcareadvantage
    PolicyNon-cystic fibrosis bronchiectasis agents (brensocatib)
    Policy CodePolicy 136.1
    Change TypeNo material change
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2027
    Next Review DateDec 18, 2027
    Key ActionSubmit prior authorization with documentation of diagnosis by chest CT, trials and >75% adherence to standard preventive therapies, and two or more exacerbations in the prior year.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Adherence MetricsProvider Actions and Documentation RequirementsDefinitionsBackground